Summitry LLC Invests $124,000 in Certara, Inc. (NASDAQ:CERT)

Summitry LLC bought a new stake in Certara, Inc. (NASDAQ:CERT) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,653 shares of the company’s stock, valued at approximately $124,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Kopion Asset Management LLC lifted its stake in Certara by 46.0% in the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after acquiring an additional 175,005 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Certara by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock valued at $5,660,000 after purchasing an additional 15,739 shares during the last quarter. Vontobel Holding Ltd. bought a new position in Certara during the fourth quarter worth about $1,295,000. Barclays PLC grew its holdings in Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after purchasing an additional 46,880 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in Certara in the fourth quarter valued at approximately $148,000. 73.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CERT has been the subject of several research analyst reports. William Blair reiterated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Stephens reaffirmed an “overweight” rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, Barclays lifted their target price on shares of Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Trading Down 4.3 %

CERT stock opened at $10.32 on Wednesday. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.18. The company has a market capitalization of $1.66 billion, a PE ratio of -51.60, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company’s 50-day simple moving average is $12.54 and its 200 day simple moving average is $11.47. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.